Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Soleno Therapeutics ( (SLNO) ) just unveiled an announcement.
On January 21, 2026, Soleno Therapeutics’ board, following a review by its independent compensation consultant and Compensation Committee, approved higher base salaries for fiscal 2026, cash bonuses for fiscal 2025, and new stock option and restricted stock unit grants for its named executive officers, with CEO Anish Bhatnagar, CFO James Mackaness, CCO Meredith Manning and SVP of Regulatory Affairs Patricia Hirano all receiving increased pay and equity awards that vest over time. On the same date, the board also adopted a Key Executive Change in Control and Severance Plan covering vice presidents and above, including the named executive officers, which standardizes severance, bonus eligibility, COBRA coverage and equity-vesting acceleration terms in the event of involuntary termination, particularly around a corporate change in control, aligning Soleno’s executive compensation and severance practices more closely with market norms and potentially strengthening leadership retention and stability during strategic transactions.
The most recent analyst rating on (SLNO) stock is a Buy with a $114.00 price target. To see the full list of analyst forecasts on Soleno Therapeutics stock, see the SLNO Stock Forecast page.
Spark’s Take on SLNO Stock
According to Spark, TipRanks’ AI Analyst, SLNO is a Neutral.
The score is driven mainly by mixed financial performance—strong revenue inflection and an excellent balance sheet, but still meaningful losses and cash burn in the TTM view. Technicals are notably weak (below major moving averages with negative MACD), while the latest earnings call was constructive (profitability, adoption, and payer coverage) but tempered by discontinuations and short-seller-related disruption.
To see Spark’s full report on SLNO stock, click here.
More about Soleno Therapeutics
Soleno Therapeutics, Inc. is a biopharmaceutical company whose leadership team includes a chief executive officer, chief financial officer, chief commercial officer and senior vice president of regulatory affairs, indicating a focus on developing and commercializing pharmaceutical products in a regulated healthcare market.
Average Trading Volume: 1,817,342
Technical Sentiment Signal: Sell
Current Market Cap: $2.35B
For a thorough assessment of SLNO stock, go to TipRanks’ Stock Analysis page.